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Objective. To evaluate the rate of preterm birth and low birth weight in the newborns of pregnant women with early and late
onset pre-eclampsia according to folic acid supplementation. Study design. Birth outcomes of newborns were evaluated in 1,017
(2.7%) pregnant women with medically recorded pre-eclampsia and 37,134 pregnant women without pre-eclampsia as reference
in the Hungarian Case-Control Surveillance System of Congenital Abnormalities, 1980–1996, in addition these study groups were
diﬀerentiated according to the supplementation of high dose of folic acid alone from early pregnancy. Results.P r e g n a n tw o m e n
with pre-eclampsia associated with a higher rate of preterm birth (10.2% versus 9.1%) and low birthweight (7.9% versus 5.6%).
There was a lower risk of preterm birth (6.8%) of newborn infants born to pregnant women with early onset pre-eclampsia after
folic acid supplementation from early pregnancy though the rate of low birthweight was not reduced signiﬁcantly. There was no
signiﬁcant reduction in the rate of preterm birth and low birthweight in pregnant women with late onset pre-eclampsia after
folic acid supplementation. Conclusion. The rate of preterm birth in pregnant women with early onset pre-eclampsia was reduced
moderately by high doses of folic acid supplementation from early pregnancy.
1.Introduction
Pre-eclampsia (PE) is frequent (2–8%) and severe com-
plications of pregnancy, and this multisystem disorder of
pregnancy is characterized by pregnancy-induced hyperten-
sion and new-onset proteinuria during the second half of
pregnancy [1–3]. PE is a major contributor to maternal
mortality if associates with eclampsia and HELLP syndrome
[4, 5]. Furthermore, since delivery is the only cure of PE,
there is a higher risk of preterm birth up to 15% [6]a n d
intrauterinegrowthretardation[7]withanincreaseininfant
mortality and morbidity.
Two important hypotheses have been generated for
the pathogenesis of PE during the last decades. The ﬁrst
hypothesis was based on the diﬀerentiation of early and late
onset PE [3] or on the two-stage model of PE [8]. The
second hypothesis was based on PE associated with placental
insuﬃciency due to hyperhomocysteinemia-related vascu-
lopathy because 3.2–7.7-fold higher risk of PE was found
in pregnant women with elevated homocysteine levels [9–
16]. Folic acid supplementation lowers plasma homocysteine
in general [17] and in patients with PE [18], thus folic
acidcontainingmultivitaminswastestedinpregnantwomen
with gestational hypertension [19] and in pregnant women
with PE [20, 21] with signiﬁcant preventive eﬀect. However,
the eﬀect of folic acid alone was not tested though most
pregnant women use only folic acid.
T h eﬁ r s to b j e c t i v eo fo u rs t u d yw a st oe v a l u a t et h eb i r t h
outcomes of pregnant women with early and late onset
PE, while the second aim was to check the eﬀect of folic2 Advances in Preventive Medicine
acid supplementation for the risk of preterm birth and low
birth weight in their newborn infants in the population-
based data set of the Hungarian Case-Control Surveillance
of Congenital Abnormalities (HCCSCA) [22].
2.MaterialandMethods
The HCCSCA is based on the comparison of exposures
studied during the pregnancy of mothers of cases with
diﬀerent congenital abnormalities and the mothers of con-
trols without any defect matched to the cases. Cases with
congenital abnormalities are selected from the Hungarian
Congenital Abnormality Registry [23] for the HCCSCA.
C o n t r o ln e w b o r n sw e r es e l e c t e df r o mt h eN a t i o n a lB i r t h
Registry of the Central Statistical Oﬃce for the HCCSCA.
In general, two newborns were matched individually to each
case according to sex, week of birth in the year when cases
were born, and district of parents’ residence of cases.
Cases were excluded from this analysis because con-
genital abnormalities may have a more robust eﬀect for
birth outcomes than PE. Thus only 38,151 control newborns
without any defect of the HCCSCA, 1980–1996, were
evaluated in this study.
Immediately after the selection of newborns an explana-
tory letter was sent to the mothers, and they were asked to
send us the prenatal maternity logbook and all other medical
records regarding the study pregnancy; these documents
were sent back after three weeks. Prenatal care was manda-
tory for pregnant women in Hungary (if somebody did not
visitprenatalcareclinic,shedidnotreceiveamaternitygrant
and leave), thus nearly 100% of pregnant women visited
prenatal care clinics, an average 7 times in their pregnancies.
The ﬁrst visit was between the 6th and 12th gestational
week. The task of obstetricians was to record all pregnancy
complications, including PE, maternal diseases, and related
drug prescriptions in the prenatal maternity logbook.
On the other hand, a structured questionnaire, a list
of medicines (drugs and pregnancy supplements), and
a printed informed consent form were also mailed to
the mothers. The questionnaire requested information on
maternal personal (e.g., employment status) and medical
data including pregnancy complications, maternal diseases,
and medicine intakes during the study pregnancy according
to gestational month. In order to standardize the answers,
mothers were asked to read the enclosed lists as a memory
aid before they replied and to send back the ﬁlled-in ques-
tionnaire and informed consent form with their signature in
our prepaid envelop.
The interval between the end of pregnancy and return
of the “information package” including prenatal maternity
logbook, questionnaire, and so forth, was 5.2 + 2.9 months.
In addition, 200 nonrespondent and 600 respondent
mothers were visited at home by regional nurses as part
of two validation studies [24, 25] because the committee
on ethics considered this followup to be disturbing to
the parents of all healthy children. Regional nurses helped
mothers to ﬁll in the questionnaire used in the HCCSCA,
evaluated the available medical documents, and obtained
data regarding the lifestyle of mothers through a cross
interview of fathers and other close relatives living together,
and ﬁnally the so-called family consensus was recorded.
Overallthenecessaryinformationwasavailableon83.0%
of pregnant women (81.3% from reply and 1.7% from home
visit). Here the 17 years’ data of the HCCSCA between
1980 and 1996 are evaluated because the data collection has
been changed since 1997 (all mothers are visited by regional
nurses), and the recent data had not been validated at the
time of the analysis.
Four types of hypertension in pregnant women were
classiﬁed: (i) chronic hypertension, (ii) PE, (iii) PE super-
imposed upon chronic hypertension, and (iv) gestational
hypertension [1, 2, 26]. Our plan was to evaluate the possible
association of these four types of hypertension in pregnant
women with the risk of other pregnancy complications and
adverse birth outcomes. The data of our study regarding
chronic and gestational hypertension were published [27],
while the evaluation of pregnant women with PE superim-
posed upon chronic hypertension is in process. Here the
birth outcomes of pregnant women with PE are presented.
Blood pressure and proteinuria were measured in
pregnant women at their visits in the prenatal care clinics.
If a new-onset proteinuria was found by the help of dipstick
screening test after the 20th gestational week, pregnant
women were referred to a detailed laboratory examination
(more than 300mg in 24h was accepted as proteinuria). PE
was diagnosed in pregnant women if they had new onset
hypertension and proteinuria. Of course, pregnant women
with secondary hypertension were also excluded from the
study.
The preliminary analysis of data showed that the diag-
nosis of PE in the questionnaire based on retrospective
maternal information was not reliable; therefore, we decided
to evaluate only medically recorded PE in the prenatal
maternitylogbook.Thereisnoconsensusintheclassiﬁcation
of early and late onset PE, SOGC [28]a n dA S H[ 29]
recommended for late onset PE less than 34 or 35 gestational
week, respectively, while others diﬀerentiate early onset
before 24 weeks gestation [30]. Thus we decided to evaluate
the onset of PE according to gestational months.
Other pregnancy complications, PE-related drug treat-
ments and other potential confounding factors such as
maternal age, birth order, marital and employment status
as indicators of socioeconomic status [31], other maternal
diseases, and folic acid supplements were also evaluated.
Only one type of 3mg folic acid (Alkaloida/ICN Hun-
gary) tablet was available in Hungary during the study
period.
Gestational age was calculated from the ﬁrst day of the
last menstrual period. Both birth weight and gestational
age at delivery were medically documented in the discharge
summary of mothers because all deliveries took place
in inpatient obstetric clinics. The rate of low (less than
2500gram) and large (4000gram or more) birth weight,
in addition to the rate of preterm (less than 37 completed
gestational weeks or less than 259 days) and postterm
(42 completed weeks or 294 days or more) birth was
calculated.Advances in Preventive Medicine 3
2.1. Statistical Analysis of Data. We used SAS version 8.02
(SAS Institute, Cary, North Carolina, USA) for statistical
analyses. The occurrence of folic acid use was compared in
pregnant women with PE and the reference group including
all pregnant women without PE. Contingency tables were
prepared for the main study variables. First, the character-
istics of pregnant women with diﬀerent study groups were
compared with the reference group using chi-square test
for categorical variables and Student t-test for quantitative
variables. Second, frequency of maternal diseases, pregnancy
complications, and related drug treatments was compared
between mothers with PE and the reference group by
ordinary logistic regression models and odds ratios (OR)
with their 95% conﬁdence intervals (CI) being evaluated.
Third, the birth outcomes of newborns were evaluated
in mothers with PE compared with the reference group
using adjusted Student t-test and OR with 95% CI using
ordinary logistic regression model. Finally birth outcomes
of newborns in pregnant women with PE were stratiﬁed
according to folic acid supplementation.
3. Results
The total number of births in Hungary was 2,146,574 during
thestudyperiod,thus38,151controlsrepresented1.8%ofall
Hungarian births. Of these 38,151 newborns, 1,017 (2.7%)
had mothers with medically recorded PE in the prenatal
maternity logbook. Of these 1,017 pregnant women with
PE, 45 (4.4%) had later eclampsia while HELLP was not
recorded.
Only 580 (57.0%) women out of total 1,017 who were
diagnosedasPEhadrecordedhistoryoftakingfolicacidsup-
plementation, while this ﬁgure was 54.4% (20,195/37,134)
in the reference group, thus pregnant women with PE used
somewhat more frequently folic acid. The indication of folic
acid supplementation was the prevention of neural tube
defects. The distribution of daily folic acid supplementation
was the following: 22.5%, 68.6%, and 8.9% of pregnant
women used one (3mg), two (6mg), and three (9mg)
tablets, respectively. Thus the estimated mean daily dose
was 5.6mg. The onset of folic acid supplementation was in
about 10% of pregnant women before conception; however,
most women started folic acid use after the ﬁrst visit in
the prenatal care clinic, that is, between the 6th and 12th
gestational weeks, thus before the onset of PE. Practically
all pregnant women continued folic acid supplementation
until the end of pregnancy. Of 580 pregnant women with
PE and folic acid use, 440 (75.9%) had medically recorded
folic acid use in the prenatal maternity logbook while this
ﬁgure was 61.3% in the reference group. Our validation
study showed that maternal information regarding folic acid
use was correct, but some women retrospectively forgot to
mention it. Folic acid containing multivitamins was used
r a r e l ya n di tc o n t a i n e dd i ﬀerent low doses of folic acid, thus
these pregnant women were excluded from the study.
Maternal characteristics are shown in Table 1. There was
no diﬀerence in mean maternal age of pregnant women with
or without PE, while mean birth order was lower by 0.3in
pregnant women with PE due to the higher proportion of
primiparous pregnant women. In addition, the diﬀerence in
the mean pregnancy order (birth + miscarriages) was 2-fold
higher in women with PE (0.4) than in pregnant women
without PE (0.2), and these ﬁndings indicate a higher rate
of miscarriages in the previous pregnancies of women with
PE. The proportion of professional women was somewhat
lower in pregnant women with PE, while their proportion of
managerialwomenandskilledworkerswassomewhathigher
compared to pregnant women without PE. Pregnant women
with PE and folic acid use were somewhat older with higher
mean birth order.
Acute and chronic maternal diseases did not show
signiﬁcantdiﬀerencesbetweenpregnantwomenwithPEand
the reference sample.
Among other pregnancy complications, threatened abor-
tion (20.8% versus 17.0%) and placental disorders (2.2%
versus 1.5%), particularly abruption placentae occurred
more frequently in pregnant women with PE than in
pregnant women without PE.
Practically all pregnant women with PE were treated
with antihypertensive drugs, most frequently nifedipine
(15.1% versus 2.2%) and methyldopa (10.5% versus 0.9%)
compared with pregnant women without PE. Dihydralazine,
metoprolol, clopamide, and furosemide were also more
frequently used by pregnant women with PE. However,
magnesium sulphate was used only in two pregnant women
with PE.
The diagnosis of PE according to gestational months
is shown in Table 2. These data reﬂect the record of PE
diagnosis in the prenatal maternity logbook, but it may be
near to the onset of this pregnancy complication due to the
frequent visits in prenatal care clinics. However, of 1,017
pregnant women with PE, 100 (9.8%) had not unambiguous
time of diagnoses. Unexpectedly the diagnosis of PE was
recordedinthefourthgestationalmonthin3.9%ofpregnant
women. In general, these pregnant women had new-onset
hypertension but proteinuria was conﬁrmed after the 20th
gestational week. The maximum was found during the last
two pregnancy months.
The birth outcomes of newborn infants born to pregnant
womenwithPEandwithoutPEasreferenceareshowninthe
lower part of Table 2. (There was no signiﬁcant diﬀerence in
the sex ratio of the study groups.) The mean gestational age
was the same in pregnant women with or without PE but
the rate of preterm birth was somewhat but not signiﬁcantly
higher in the group of pregnant women with PE (10.2%
versus 9.1%). The mean birth weight of newborn infants
borntopregnantwomenwithPEwassomewhat(41g)larger
compared to the newborns of pregnant women without PE
andthis smalldiﬀerence wassigniﬁcant. Onthe contrary, the
rate of low birth weight newborns was higher in the group of
pregnant women with PE (7.9% versus 5.6%), and this 40%
increase is signiﬁcant on both statistical and clinical aspects.
In the next step, newborns were evaluated according to
gestational age and birth weight groups in pregnant women
with PE and without PE as reference. A characteristic U-
shaped curve was shown; the previously mentioned higher
rate of preterm birth and low birth weight associated with
a higher rate of postterm birth (11.2% versus 10.1%; OR4 Advances in Preventive Medicine
Table 1: Characteristics of pregnant women without pre-eclampsia (PE) as a reference and with PE, in addition pregnant women with PE
supplemented with folic acid.
Variables Pregnant women Pregnant women with PE + folic acid
Without PE (N = 37,134) With PE (N = 1,017) Folic acid (N = 580)
Maternal age (yr) No. % No. % No. %
19 or less 3,191 8.6 86 8.5 43 7.4
20–29 26,877 72.4 725 71.3 410 70.7
30 or more 7,066 19.0 206 20.3 127 21.9
Mean ± S.D. 25.5 4.9 25.5 5.0 25.7 4.9
Birth order
1 17,603 47.4 706 69.4 340 58.6
2 or more 19,529 52-6 311 30.6 240 41.4
Mean ± S.D. 1.7 0.9 1.4 0.9 1.6 1.1
Pregnancy order
1 15,780 42.5 540 53.1 301 51.9
2 or more 21,354 57.5 477 46.9 279 48.1
Mean ± S.D. 1.9 1.2 1.8 1.2 1.8 1.1
Unmarried 1,443 3.9 29 2.9 14 2.4
Employment status Professional 4,330 11.7 93 9.1 56 9.7
Managerial 9,960 26.8 305 30.0 181 31.2
Skilled worker 1,551 31.1 357 35.1 202 34.8
Semiskilled worker 5,998 16.2 163 16.0 89 15.3
Unskilled worker 2,140 5.8 47 4.6 24 4.1
Housewife 2,310 6.2 40 3.9 22 3.8
Others 841 2.3 12 1.2 6 1.0
Table 2: Onset (diagnosis) of pregnant women with pre-eclampsia according to gestational month and their birth outcomes.
Gestational months No. % Gestational age (wk) Birth weight (g) Preterm birth Low birth weight
Mean S.D. Mean S.D. No. % No. %
IV 36 3.9 39.2 2.7 3,365 540 7 19.4 2 5.6
V 109 11.9 39.5 1.9 3,414 523 6 5.5 3 2.8
VI 115 12.5 39.3 2.4 3,339 660 14 12.2 12 10.4
VII 185 20.2 39.1 2.3 3,234 622 25 13.5 22 11.9
VIII 246 26.8 39.1 2.2 3,263 603 29 11.8 24 9.8
IX 226 24.7 39.9 1.7 3,383 503 9 4.0 9 4.0
Subtotal 917 100.0 39.4 2.1 3,318 583 90 9.8 72 7.9
Unknown 100 9.8 39.1 2.2 3,296 615 14 14.0 8 8.0
Total 1,017 100.0 39.4 2.1 3,316 586 104 10.2 80 7.9
Reference 37,134 — 39.4 2.0 3,275 509 3,392 9.1 2,087 5.6
Comparison t = 0.0 P = 1.0 t = 2.5 P = .01 1.1 (0.9–1.4)∗ 1.4 (1.1–1.8)∗
With folic acid 580 57.0 39.5 2.0 3,334 577 51 8.8 42 7.2
Without folic acid 437 43.0 39.2 2.2 3,291 597 53 12.1 38 8.7
Comparison t = 2.3 P = .03 t = 1.2 P = .07 0.7 (0.5–1.0)∗ 0.8 (0.5–1.3)∗
∗OR (95% CI).
with 95% CI: 1.1. 0.7–1.7) and large birth weight (10.9%
versus 7.4%; OR with 95% CI: 1.5, 1.2–2.0). However, these
diﬀerences reached the level of signiﬁcance only in low and
large birth weight, and the mean birth weight was higher
both in term and the postterm births.
The gestational age at delivery and birth weight were
moderately modiﬁed by folic acid supplementation from
the early pregnancy (Table 2). The mean gestational age
was 0.3 week longer in pregnant with PE after folic acid
supplementation compared to pregnant women with PE,
but without folic acid use, These data were in agreement
with their lower rate of preterm births (8.8% versus 12.1%).
However, folic acid supplement associated with only 46 g
largermeanbirthweightandwithmoderatereductionoflow
birth weight (7.2% versus 8.7%) and these diﬀerences were
notsigniﬁcant.IfonlymedicallyrecordedfolicaciduseswereAdvances in Preventive Medicine 5
Table 3: Distribution of gestational age (preterm, term, postterm) and birth weight (low, average, large) groups in pregnant women without
PE (as reference) and with PE, in addition in pregnant women with PE with folic acid supplementation.
Gestational age groups Pregnant women without PE Pregnant women with PE Pregnant women with PE + FAS
Birth weight (g) Birth weight (g) Birth weight (g)
No. % Mean S.D. No. % Mean S.D. No. % Mean S.D.
−37 3,392 9.1 2,486 435 104 10.2 2,401 460 51 8.8 2,440 401
38–41 29,994 80.8 3,322 428 799 78.6 3,376 491 460 79.3 3,384 506
42− 3,748 10.1 3,612 485 114 11.2 3,729 473 69 11.9 3,663 468
Total 37,134 100.0 3,275 509 1,017 100.0 3,316 580 580 100.0 3,334 57
Birth weight groups Gestational age (wk) Gestational age (wk) Gestational age (wk)
−2499 2,087 5.6 35.6 3.3 80 7.9 35.7 2.8 42 7.2 36.1 2.8
2500–3999 32,286 87.0 39.5 1.7 826 81.2 39.5 1.7 471 81.2 39.6 1.7
4000− 2,761 7.4 41.0 1.1 111 10.9 41.0 1.2 67 11.6 40.7 1.3
Total 37,134 100.0 39.4 2.0 1,017 100.0 39.4 2.1 580 100.0 39.5 2.0
Table 4: The eﬀect of folic acid for birth outcomes of pregnant women with early and late onset PE.
Gestational months No. % Gestational age (wk) Birth weight (g) Preterm birth Low birth weight
Mean S.D. Mean S.D. No. % No. %
All
IV-VI 260 28.4 39.4 2.2 3,374 589 27 10.4 17 6.5
VII-IX 657 71.6 39.4 2.1 3,296 579 63 9.6 55 8.4
Total 917 100.0 39.4 2.1 3,318 583 90 9.8 72 7.9
With folic acid supplementation
IV-VI 147 27.2 39.6 2.1 3,419 560 10 6.8 7 4.8
VII-IX 394 72.8 39.4 2.0 3,302 575 38 9.6 32 8.1
Total 541 100.0 39.5 2.0 3,334 573 48 8.9 39 7.2
considered,thedataofbirthoutcomesdidnotdiﬀerfromthe
total data.
However, the eﬀect of folic acid increased the rate of
postterm birth (11.9% versus 11.2%) with smaller mean
birth weight and the rate of large birth weight (11.6% versus
10.9%) with shorter mean gestational age (Table 3), though
these changes did not reach the level of signiﬁcance.
The birth outcomes were evaluated according to the
onset of PE (Table 2). There was no obvious trend in mean
gestational age and birth weight depending on the onset of
PE. The ﬁfth and last ninth months had longer gestational
age with the lower rate of preterm birth. The fourth month
due to possible diagnostic bias associated with extremely
high preterm birth. Obviously the major risk for adverse
birth outcomes was connected with the onset of PE between
the sixth and eighth gestational months.
Finally the eﬀect of folic acid for birth outcomes was
evaluatedinpregnantwomenwithearly(IV–VImonths)and
late (VII–IX months) onset PE in the study (Table 4). Folic
acid was able to reduce signiﬁcantly the rate of preterm birth
(OR with 95% CI: 0.41, 0.18–0.94) in pregnant women with
early onset PE. There was also a reduction in the rate of low
birth weight rate after folic acid use in early pregnancy of
women with early onset PE but this reduction did not reach
the level of signiﬁcance (OR with 95% CI: 0.52, 0.19–1.40).
4. Discussion
The primary aim of the study was to evaluate birth
outcomes of pregnant women with early (“placental”) and
late (“maternal”) PE. The risk of adverse birth outcomes
cannot be diﬀerentiated according to early and late onset PE
deﬁned in our study, because the onset between sixth and
eighth gestational months associated with a higher risk of
preterm birth and low birth weight. The secondary aim of
the study was to estimate the possible eﬀect of folic acid
for the risk of preterm birth and low birth weight of their
newborns. On one hand, the high dose of folic acid used in
early pregnancy reduced the rate of preterm birth but not
modiﬁed signiﬁcantly the higher rate of low birth weight,
that is, intrauterine growth retardation in pregnant women
with early PE. On the other hand, this preventive eﬀect of
folic acid was not observed in pregnant women with late PE;
in fact, there was somewhat but not signiﬁcantly higher rate
o fp r e t e r mb i r t ha n dl o wb i r t hw e i g h ti np r e g n a n tw o m e n
with late PE after folic acid supplementation.
The prevalence of PE was 2.7% in pregnant women with-
out PE superimposed upon chronic hypertension. Eclampsia
is deﬁned as the occurrence of tonic-clonic seizures in
pregnant women with PE, and recently eclampsia has
manifested only in 1-2% of women with severe PE [3].
However, this ﬁgure was 4.4 % in the study explained by the6 Advances in Preventive Medicine
possible overdiagnoses and mainly by the lack of magnesium
sulphate treatment in Hungary during the study period.
The primary goal is to prevent the manifestation of
PE with maternal complications; however, a reasonable
secondary goal is to reduce the adverse birth outcomes of
pregnant women with PE. The rate of preterm births (10.2%
versus 9.1%) and mainly of low birth weight (7.9% versus
5.6%) was higher in the newborns of pregnant women with
PE than in the newborns of pregnant women without PE,
though these ﬁgures were lower than rates found in previous
studies [32, 33]. These diﬀerences may reﬂect the improve-
ment of medical care of pregnant women with PE. However,
the unexpected ﬁndings of the study were the higher rate
of postterm birth (11.2% versus 10.1%) and mainly of
large birth weight (10.9% versus 7.4%) in the newborns of
pregnantwomenwithPE.Thelatterexplainsthelargermean
birth weight of newborn infants born to pregnant women
withPEcomparedtothenewbornsofpregnantwomenwith-
out PE. The mild U-shaped distribution of gestational weeks
is in agreement with the same mean gestational age at deliv-
ery in the groups of pregnant women with or without PE.
The use of folic acid modiﬁed these ﬁndings; the mean
gestational age was somewhat longer with a lower rate of
preterm birth. Similar beneﬁcial eﬀect was not found in the
rate of low birth weight newborns. However, an important
observation of our study is that the beneﬁcial eﬀect of high
dose of folic acid use from early pregnancy occurred only in
pregnant women with early (placental) onset PE.
Our previous study showed that the high dose of folic
acid during pregnancy associated with a minor increase of
birth weight but a longer gestational age at delivery and
signiﬁcant reduction in the rate of preterm birth [34]. In
this study, we found similar ﬁndings, but these eﬀects were
moderate, thus the maternal pathological conditions are
important in the eﬀect of folic acid.
The major expected beneﬁt of antihypertensive therapy
is the reduction of hypertension of pregnant women with
PE [27] to reduce maternal complications and adverse birth
outcomes. However, it was not successful in many women in
our material. Magnesium sulphate is recommended for the
treatment of severe PE [35, 36]; unfortunately, it was used
rarely in Hungary.
Our study conﬁrmed the role of nulliparity [3] and the
higher rate of previous miscarriages [37] in the origin of PE.
The strengths of the HCCSCA are that it is a population-
based large data set including 1,017 pregnant women with
prospectively and medically recorded PE in an ethnically
homogeneous European (Caucasian) population. We were
able to diﬀerentiate PE from the other types of hyperten-
sion in pregnant women. Additional strengths are med-
ically recorded other pregnancy complications and birth
outcomes, in addition to the available data of potential
confounders.
However, this data set also has limitations. (i) Other
pregnancy outcomes, for example, miscarriages were not
known in the study pregnancy. (ii) Lifestyle factors could not
be evaluated in the total data set due to the unreliability of
maternal self-reported data [38], though smoking seems to
be protective for PE [39–41].
In conclusion, a higher risk of preterm births and mainly
low birth weight was found in the newborns of pregnant
women with PE. The use of high dose of folic acid from
early pregnancy resulted in a reduction of preterm birth
in pregnant women with early onset PE; however, similar
beneﬁcial eﬀect was not found in the rate of low birth
weight and in pregnant women with late onset PE. The
clinical importance of these statistically signiﬁcant changes
is necessary to be validated in well-controlled prospective
studies.
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